Back to Search Start Over

Systemic enhancement of antitumour immunity by peritumourally implanted immunomodulatory macroporous scaffolds.

Authors :
Majedi FS
Hasani-Sadrabadi MM
Thauland TJ
Keswani SG
Li S
Bouchard LS
Butte MJ
Source :
Nature biomedical engineering [Nat Biomed Eng] 2023 Jan; Vol. 7 (1), pp. 56-71. Date of Electronic Publication: 2022 Dec 22.
Publication Year :
2023

Abstract

A tumour microenvironment abundant in regulatory T (T <subscript>reg</subscript> ) cells aids solid tumours to evade clearance by effector T cells. Systemic strategies to suppress T <subscript>reg</subscript> cells or to augment immunity can elicit autoimmune side effects, cytokine storms and other toxicities. Here we report the design, fabrication and therapeutic performance of a biodegradable macroporous scaffold, implanted peritumourally, that releases a small-molecule inhibitor of transforming growth factor β to suppress T <subscript>reg</subscript> cells, chemokines to attract effector T cells and antibodies to stimulate them. In two mouse models of aggressive tumours, the implant boosted the recruitment and activation of effector T cells into the tumour and depleted it of T <subscript>reg</subscript> cells, which resulted in an 'immunological abscopal effect' on distant metastases and in the establishment of long-term memory that impeded tumour recurrence. We also show that the scaffold can be used to deliver tumour-antigen-specific T cells into the tumour. Peritumourally implanted immunomodulatory scaffolds may represent a general strategy to enhance T-cell immunity and avoid the toxicities of systemic therapies.<br /> (© 2022. The Author(s), under exclusive licence to Springer Nature Limited.)

Details

Language :
English
ISSN :
2157-846X
Volume :
7
Issue :
1
Database :
MEDLINE
Journal :
Nature biomedical engineering
Publication Type :
Academic Journal
Accession number :
36550304
Full Text :
https://doi.org/10.1038/s41551-022-00977-0